TABLE 3.

Statistical analysis of dose-normalized omadacycline pharmacokinetic parameters on days 1 and 5 of dosing^a

Day and parameter	Treatment (mg)	n	Geometric LS means	Treatment comparison	Ratio of geometric LS means (%)	90% CI of ratio
Day 1
AUC0–24/dose, ng · h/ml/mg	300	25	21.32
	450	24	18.64	450/300	87.44	77.41–98.77
	600	24	16.18	600/450	86.79	76.71–98.20
				600/300	75.89	67.20–85.71
Cmax/dose, ng/ml/mg	300	25	2.09
	450	24	1.81	450/300	86.71	76.17–98.71
	600	24	1.54	600/450	85.26	74.76–97.23
				600/300	73.92	64.95–84.14
Day 5
AUC0–24/dose, ng · h/ml/mg	300	23	30.09
	450	24	28.83	450/300	95.82	90.39–101.59
	600	23	26.46	600/450	91.78	86.58–97.30
				600/300	87.95	82.96–93.25
Cmax/dose, ng/ml/mg	300	23	2.62
	450	24	2.32	450/300	88.58	83.19–94.32
	600	23	2.11	600/450	90.72	85.20–96.60
				600/300	80.36	75.47–85.58

^aResults are for PK population and were determined by ANOVA; see Materials and Methods for details. One subject during 300-mg omadacycline dosing and 1 subject during 600-mg omadacycline dosing vomited before reaching PK steady state on day 5. These subjects met criteria for exclusion from PK analyses and are not included in the day 5 summary. CI, confidence interval; LS, least squares.